La Rochelle

• NAlmefene versus placebo in addition to treatment as usual on craving in Behavioural Addictions (NABAb) Recruiting
  2022-500085-96-00 5 2023-03-31 Patients with gambling disorder or sexual addiction or food addiction
• Maintenance Pembrolizumab at Usual or Low doSE in non-squamous lung cancer: a non-inferiority study Recruiting
  2023-503481-23-00 5 2023-03-20 Maintenance treatment in metastatic non-squamous lung cancer
• IFM2020-05-BENEFIT-Multicenter Open label Phase 3 study of Isatuximab plus Lenalidomide and Dexamethasone with/without Bortezomib in the Tre … Recruiting
  2024-517215-67-00 5 2021-06-11 Newly diagnosed Non-Frail transplant Ineligible Multiple Myeloma elder
• A Phase 3 study to assess efficacy, safety and tolerability of remibrutinib in adult and adolescent patients with moderate to severe hidrade … Ended recruitment
  2024-513266-19-00 5 2025-06-13 Hidradenitis Suppurativa (HS)
• A Proof of Concept study to assess the efficacy, safety and tolerability of itepekimab (anti­IL­33 mAb) in participants with chronic rhinosi … Ended recruitment
  2024-515576-12-00 4 2025-03-20 Respiratory tract diseases
• Management of Anticoagulant Therapy monitored by an implantable device with telecardiology in patients with Acute Coronary Syndrome associat … Ended recruitment
  2024-515433-15-02 6 2025-01-29 acute coronary syndrome
• CLINICAL STUDY TO TEST STEM CELLS FOR THE TREATMENT OF LONG-TERM, NON-HEALING VENOUS LEG ULCERS Ended recruitment
  2024-512720-11-00 5 2025-01-16 chronic venous ulcers (CVU)
• PRODIGE 49 - OSCAR: Systemic oxaliplatin or in intra-arterial chemotherapy combined with LV5FU2 ± Irinotecan, and targeted therapy, in first … Ended recruitment
  2024-518553-41-00 5 2024-11-08 colon cancer and rectal with liver metastasis
• A Phase 3 Study of DB-1303 vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer Ended recruitment
  2023-507333-17-00 5 2024-04-15 HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
• TocilizuMab discontinuAtion in GIant Cell Arteritis Ended recruitment
  2023-505515-21-00 5 2024-04-02 Giant Cell Arteritis
• 52 weeks double-blind, double-dummy, randomized placebo-controlled trial to evaluate safety, efficacy and tolerability of remibrutinib in co … Ended recruitment
  2022-502161-19-00 5 2024-03-12 Chronic Spontaneous Urticaria
• AITIK-Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System Ended recruitment
  2024-515479-36-00 5 2023-07-05 Chronic Myeloid Leukemia
• Dupilumab step-down strategy to maintain remission in adult and adolescents patients with atopic dermatitis: a non-inferiority randomized tr … Ended recruitment
  2022-501179-23-00 6 2023-03-08 atopic dermatitis
• A Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in R/R DLBCL Ended recruitment
  2023-504830-23-00 5 2020-12-16 B-cell Lymphoma
• A Phase 3 Study Comparing Lenalidomide and Daratumumab Subcutaneous Injection (R-Dara SC) vs Lenalidomide and Dexamethasone (Rd) in Frail Su … Ended recruitment
  2024-514088-25-00 5 2019-10-07 Multiple Myeloma
• Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer Ended recruitment
  2024-512165-13-00 4 2019-05-13 Localised unresectable adenocarcinoma or squamous cell carcinoma of th
• Maintaining or Stopping immunosuppressive Therapy in patients with ANCA vasculitis and End-stage Renal disease: a prospective, multicenter, … Ended recruitment
  2024-512470-10-00 11 2018-02-02 End-stage Renal disease
• PRODIGE 34 - ADAGE: Randomised phase III study evaluating adjuvant chemotherapy after resection of stage III colon adenocarcinoma in patient … Ended recruitment
  2024-518741-21-00 4 2014-12-23 colon cancer
• Use of electronic cigarettes for smoking cessation Halted
  2024-518135-10-00 5 2024-10-31 Smokers smoking at least 10 cigarettes/day in the past year
• Long-Term Extension Study (AtDvance) to Evaluate the Safety and Efficacy of GSK1070806 in Participants with Moderate to Severe Atopic Dermat … Ended
  2023-508474-29-00 4 2024-10-30 Dermatitis, Atopic
• Proof-of-concept study evaluating subcutaneous amlitelimab in adult participants with moderate to severe hidradenitis suppurativa. Ended
  2023-505803-22-00 4 2024-04-15 Hidradenitis
• A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Dose Finding study to evaluate the Efficacy, Safety, Pharmacokinet … Ended
  2023-505414-15-00 4 2024-04-10 Dermatitis, Atopic
• A Ph2 dose-finding study (MARS-17) to evaluate the efficacy and safety of GSK3858279 in adults with knee osteoarthritis pain. Ended
  2022-502799-22-00 4 2023-11-29 Knee osteoarthritis pain
• SENS-401 to Prevent the Ototoxicity induced by Cisplatin in Adult Subjects with a Neoplastic Disease Ended
  2024-511713-38-00 4 2022-12-30 Cisplatine induced hearing loss

Showing 25–48 of 50 trials